.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Fuji
Merck
Novartis
Chubb
Harvard Business School
Johnson and Johnson
QuintilesIMS
Argus Health
Boehringer Ingelheim

Generated: June 24, 2017

DrugPatentWatch Database Preview

Prasugrel hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for prasugrel hydrochloride and what is the scope of prasugrel hydrochloride patent protection?

Prasugrel hydrochloride
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Prasugrel hydrochloride has sixty-seven patent family members in thirty-one countries.

There are nineteen drug master file entries for prasugrel hydrochloride. Three suppliers are listed for this compound.

Summary for Generic Name: prasugrel hydrochloride

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list19
Suppliers / Packagers: see list3
Bulk Api Vendors: see list24
Clinical Trials: see list2,408
Patent Applications: see list28
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:prasugrel hydrochloride at DailyMed

Pharmacology for Ingredient: prasugrel hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-002Jul 10, 2009RXYesYes5,288,726*PED► SubscribeY► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-002Jul 10, 2009RXYesYes► Subscribe► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-001Jul 10, 2009RXYesNo► Subscribe► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-001Jul 10, 2009RXYesNo8,404,703*PED► SubscribeY► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-001Jul 10, 2009RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: prasugrel hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: prasugrel hydrochloride

Country Document Number Estimated Expiration
China1074446► Subscribe
Czech Republic9202784► Subscribe
HungaryT66195► Subscribe
Denmark0542411► Subscribe
Finland924002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PRASUGREL HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0542411/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
C021/2009Ireland► SubscribeSPC021/2009: 20091119, EXPIRES: 20170908
0397Netherlands► Subscribe300397, 20120909, EXPIRES: 20170908
C0031France► SubscribePRODUCT NAME: PRASUGREL; NAT. REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225; FIRST REGISTRATION: EU/1/08/503/001/-014 20090225
589Luxembourg► Subscribe91589, EXPIRES: 20170909
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Chubb
Accenture
Moodys
Novartis
Daiichi Sankyo
Baxter
Queensland Health
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot